



**HAL**  
open science

## The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses

Carla Eller, Laura Heydmann, Che Colpitts, Eloi Verrier, Catherine Schuster,  
Thomas F. Baumert

### ► To cite this version:

Carla Eller, Laura Heydmann, Che Colpitts, Eloi Verrier, Catherine Schuster, et al.. The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses. Cellular and Molecular Life Sciences, 2018, 75 (21), pp.3895-3905. 10.1007/s00018-018-2892-y . hal-02374180

**HAL Id: hal-02374180**

**<https://hal.science/hal-02374180v1>**

Submitted on 17 Jan 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



28 **Abstract**

29 Chronic hepatitis B, C and D virus (HBV, HCV and HDV) infections are a major cause of liver disease and cancer  
30 worldwide. Despite employing distinct replication strategies, the three viruses are exclusively hepatotropic and  
31 therefore depend on hepatocyte-specific host factors. The sodium taurocholate co-transporting polypeptide  
32 (NTCP), a transmembrane protein highly expressed in human hepatocytes that mediates the transport of bile acids,  
33 plays a key role in HBV and HDV entry into hepatocytes. Recently, NTCP has been shown to modulate HCV  
34 infection of hepatocytes by regulating innate antiviral immune responses in the liver. Here we review the current  
35 knowledge of the functional role and the molecular and cellular biology of NTCP in the life cycle of the three  
36 major hepatotropic viruses, highlight the impact of NTCP as an antiviral target and discuss future avenues of  
37 research.

38

39 **Keywords:** Liver cell biology, bile acid transport, host factor, anti-viral therapy, hepatocytes.

40

41 **Introduction**

42 Every year, viral hepatitis is estimated to cause around 1.3 million deaths worldwide, mainly through chronic liver  
43 disease and hepatocellular carcinoma (HCC). Approximately 95% of these deaths are caused by hepatitis B and C  
44 viruses (HBV, HCV) [1]. Despite the availability of an effective vaccine for HBV, 250 million people are  
45 chronically infected by the virus worldwide [2]. An estimated 5% of HBV patients are co-infected with hepatitis D  
46 virus (HDV), a satellite virus hijacking HBV envelope proteins to assemble its infectious viral particles. HDV co-  
47 infection worsens the outcome of HBV infection and treatment of HBV-HDV co-infected patients is less effective  
48 [3, 4]. Moreover, around 70 million people are living with chronic HCV infection and, despite the existence of  
49 effective curative strategies, the incidence of HCV is still increasing [3].

50 Remarkable progress has recently been made for treatment of HCV infection. The development and  
51 approval of direct acting antivirals (DAAs) specifically targeting viral proteins now allows for HCV cure, but these  
52 therapies remain inaccessible for the majority of HCV patients [5]. For chronic HBV infection, two therapeutic  
53 approaches are used to suppress viral replication: pegylated interferon and nucleos(t)ide analogues (NUCs). While  
54 these treatments allow control of HBV infection, viral eradication is rare and, in most cases, lifelong therapy is  
55 required [6]. For patients with chronic HBV/HDV co-infection, the current treatment options are limited to  
56 interferon-alpha (IFN $\alpha$ ) and its pegylated derivative. Furthermore, although current antivirals decrease the risk of  
57 HCC, they are not sufficient to eliminate the risk [7, 8]. In order to effectively combat these hepatotropic viruses,

58 it is necessary to improve existing therapies and uncover new strategies for prevention and treatment of viral  
59 hepatitis.

60 Alternative strategies against chronic HBV and HCV infection include host-targeting agents (HTA),  
61 which target host factors required for viral replication. HTAs have been shown to be promising candidates for the  
62 prevention and treatment of infections by various pathogens, including HBV and HCV [9–11]. This approach  
63 requires a profound understanding of the viral life cycle and the virus-host interactions involved. Indeed, the  
64 identification of the human sodium taurocholate co-transporting polypeptide (NTCP) as a functional receptor for  
65 HBV/HDV infection [12, 13] opened perspectives for new antiviral strategies. Several entry inhibitors for  
66 treatment of HBV infection targeting NTCP are now in development [14–19]. Furthermore, this crucial discovery  
67 has allowed the development of novel infectious model systems that will enable an improved understanding of the  
68 complete HBV/HDV viral life cycle [20]. However, the regulatory role of NTCP in HCV host cell infection, and  
69 its potential immunomodulatory activities in hepatocytes, should not be overlooked. The aim of this review is to  
70 summarize what is known about the interactions of NTCP with three major hepatitis viruses during infection, to  
71 describe the molecular mechanisms, and to highlight possible applications in research and therapy.

72

### 73 **Sodium taurocholate co-transporting polypeptide, a bile acid transporter**

74 The circulation of bile and bile components between human intestine enterocytes and liver parenchymal cells is  
75 known as the enterohepatic circulation (EHC) [21]. In the liver, bile acids are mainly involved in cholesterol  
76 metabolism and elimination of toxic compounds [22]. Interestingly, bile acids have also been shown to inhibit  
77 interferon (IFN) signaling pathways, resulting in reduced expression of IFN-stimulated genes (ISG) [23, 24]. In  
78 hepatocytes, bile acid homeostasis is maintained by the interplay between uptake, synthesis and secretion of bile  
79 acids. The major hepatic uptake transporter for conjugated bile acids in humans is sodium taurocholate  
80 co-transporting polypeptide (NTCP) [25]. NTCP is predominantly expressed at the hepatic basolateral membrane  
81 and is involved in the recycling of bile acids from portal blood to hepatocytes in a sodium-dependent manner [21].  
82 NTCP is a member of the solute carrier family SLC10 and is encoded by *SLC10A1* [26, 27]. *SLC10A1* mRNA is  
83 translated into a 349 amino acid glycosylated phosphoprotein with seven or nine transmembrane domains [21, 28–  
84 31]. While the exact function of some SLC10 family members remains unknown, all of them are thought to be  
85 sodium-dependent transporters [21]. Interestingly, bile acid transport through NTCP can be blocked by small  
86 molecules already in clinical use, such as cyclosporine A (CsA, an immunosuppressive drug used in  
87 transplantation) or ezetimibe (used for hypercholesterolemia) [16, 32].

88           Hepatic bile acid metabolism is tightly regulated, including at the transcriptional level (see Figure 1) [33].  
89   Upon bile acid activation, the nuclear factor Farnesoid X Receptor (FXR) indirectly downregulates several target  
90   genes through transcriptional induction of the small heterodimer partner (SHP) [34, 35], including the first and  
91   rate-limiting enzyme in bile acid biosynthesis cholesterol 7 $\alpha$ -hydroxylase (CYP7A1) [36, 37]. FXR also directly  
92   activates the expression of the bile salt export pump (BSEP, ABCB11), which is expressed at the apical membrane  
93   and secretes conjugated bile acids into the bile canaliculus in an ATP-dependent manner [38, 39]. FXR does not  
94   directly interact with the promoter of human *SLC10A1* but induces the expression of different factors to indirectly  
95   repress *slc10a1* expression in rat and mouse, although mechanisms of transcriptional regulation of human NTCP  
96   remain unknown [40–42]. In hepatic inflammation, the cytokines tumor necrosis factor alpha (TNF- $\alpha$ ), interleukin  
97   (IL)-1 $\beta$ , and IL-6 downregulate mRNA levels of *SLC10A1* and reduce the transporter protein expression [43–45].  
98   The downregulation of NTCP expression in the human liver has been implicated in several cholestasis pathologies.  
99   The reduction of NTCP expression could explain impaired hepatic bile acid uptake, resulting in cholestasis and  
100   jaundice. Several studies have shown a downregulation of bile salt transporters in primary biliary cirrhosis [46,  
101   47]. Interestingly, a recent study showed a suppression of NTCP expression via cyclin D1 in hepatocellular  
102   carcinoma (HCC) [48]. These data may explain the low expression level of NTCP in HCC-derived cell lines, such  
103   as Huh7 and clones or HepG2.

104           The localization and membrane expression of NTCP is controlled by post-translational mechanisms [49].  
105   For example, cyclic adenosine monophosphate (cAMP) plays a role in stimulating the dephosphorylation and  
106   membrane translocation of NTCP (see Figure 1) [50–52]. Sequencing analysis of NTCP revealed the existence of  
107   several ethnic-dependent single nucleotide polymorphisms (SNPs) which may alter NTCP activities [53]. For  
108   example, mutation S267F, found in 7.5% of allele frequencies in Chinese Americans, is associated with an almost  
109   complete loss of bile acid uptake function. However, no pathologies have been described resulting from these  
110   NTCP polymorphisms and their clinical roles remain controversial [54]. Besides its major role in the bile acid  
111   uptake system, Yan *et al.* described the crucial role of NTCP on HBV and HDV entry [12]. For the time being,  
112   NTCP remains the only described HBV and HDV entry receptor.

113

114

115 **NTCP is a host factor for HBV/HDV infection**

116 Hepatitis B virus is the prototypic member of the *Hepadnaviridae* family of small enveloped hepatotropic DNA  
117 viruses. Its envelope consists of three different forms of the HBV surface protein (HBsAg) – the small (S), middle  
118 (M) and large (L) proteins. Importantly, the preS1-domain of L envelope protein is known to bind the hepatocyte  
119 cell surface and is required for HBV and HDV entry [55]. The HBV capsid is comprised of HBV core protein  
120 (HBcAg) and encapsidates a partially double-stranded relaxed circular DNA (rcDNA) genome of 3.2 kilobases.  
121 Upon infection of hepatocytes, genomic rcDNA is converted into covalently closed circular DNA (cccDNA), a  
122 minichromosome-like structure that persists in the nucleus as a central transcription template for all viral RNAs  
123 [56]. The presence of cccDNA in the nucleus is thought to be responsible for viral rebound after withdrawal of  
124 NUC therapy that targets reverse transcription, a late step in the HBV life cycle. Therefore, removal of cccDNA  
125 from HBV-infected hepatocytes will be essential to achieve the goal of HBV cure [57].

126 HDV is a defective hepatotropic virus which depends on HBV surface proteins for assembly of infectious  
127 virions and viral entry [58]. The HDV genome is a negative single-stranded circular RNA of nearly  
128 1700 nucleotides containing one functional open reading frame, which encodes the hepatitis delta protein (HDAg)  
129 expressed in small and large form. Replication of HDV RNA and transcription of HDAg mRNA in the nucleus  
130 depends on host cell polymerases, including DNA-dependent RNA polymerase II. Both forms of the delta protein  
131 are then produced and reimported in the nucleus where they bind to genomic RNA to form the ribonucleoprotein  
132 (RNP), which is then exported into the cytoplasm and is associated with HBV envelope proteins to form a mature  
133 HDV virion [59]. Thus, HDV enters hepatocytes using the same pathways as HBV, and depends on the same host  
134 factors for host cell binding and entry. HDV is therefore a useful surrogate model for HBV entry.

135 The first step of viral infection is virion binding to attachment factors and receptors at the host cell surface.  
136 This specific interaction between viral surface proteins and host entry receptors often determines the tissue tropism  
137 and host range of the virus [60]. HBV and its satellite virus HDV share HBV envelope proteins and are known to  
138 exclusively infect human, chimpanzee and tree shrew (*Tupaia belangerii*) hepatocytes, suggesting the involvement  
139 of species- and liver-specific cell surface factors in the common entry process of these viruses [20]. Two elements  
140 of the HBV envelope proteins are necessary for interaction with these factors. One determinant of infectivity  
141 resides in the surface-exposed cysteine-rich antigenic loop (AGL), a polypeptide located in the S domain of all  
142 three envelope proteins [61, 62]. The second known infectivity determinant is a receptor binding site in the N-  
143 terminal pre-S1 domain of the L-HBsAg [55]. This domain is post-translationally modified by addition of myristic

144 acid [63], and this myristoylation is essential for virion infectivity [64, 65]. A synthetic myristoylated peptide  
145 comprising the N-terminal amino acids 2 to 78 of the pre-S1 domain prevents HBV infection [66].

146 As for many viruses [67, 68], HBV/HDV infection requires the initial attachment to the  
147 glycosaminoglycan (GAG) side chains of heparan sulfate proteoglycans (HSPGs) [69]. Both the antigenic loop of  
148 all HBV envelope proteins and the preS1-region of HBsAg-L are involved in this interaction [69, 70]. Indeed,  
149 glypican-5 (GPC5), a member of the glypican family of HSPGs, acts as an entry factor for HBV and HDV (see  
150 Figure 2) [71]. After this initial step of HBV/HDV attachment to HSPGs, the virions bind to a high-affinity receptor  
151 via the preS1-domain [72], allowing uptake into hepatocytes. Despite the discovery of several preS1-interacting  
152 proteins that did not affect HBV infectivity [73–78], the identity of the HBV/HDV entry receptor remained unclear  
153 until 2012, when Yan *et al.* identified NTCP as a functional receptor for HBV and HDV infection. Using a labeled  
154 preS1 peptide as a bait in *Tupaia* hepatocytes, a mass spectrometry purification of preS1-bound proteins, and  
155 validation in human hepatocytes, it was shown that NTCP specifically interacts with the HBV receptor-binding  
156 domain preS1, allowing viral entry [12]. Zhong *et al.* showed that *Tupaia* NTCP mediates entry of woolly monkey  
157 HBV, indicating that NTCP orthologs act as a common cellular receptor for known primate hepadnaviruses [79].  
158 Differential gene expression patterns between non-susceptible undifferentiated and susceptible differentiated  
159 HepaRG cells validated the role of NTCP as a specific receptor for HBV and HDV [13]. Moreover, silencing of  
160 NTCP in primary *Tupaia* hepatocytes (PTH) or differentiated HepaRG cells inhibits HBV and HDV infection [12,  
161 13]. Exogenous expression of NTCP directly renders non-susceptible hepatoma cell lines susceptible to HBV and  
162 HDV infection, while entry inhibitors derived from the preS1 peptide efficiently inhibit this infection [12]. In  
163 addition, the S267F mutant of NTCP, conferring a loss of bile acid uptake function, is significantly associated with  
164 resistance to chronic hepatitis B and decreased risk of cirrhosis and liver cancer development, supporting the role  
165 of NTCP as cellular receptor for HBV in human infection [80–82]. However, S267F homozygote patients can still  
166 be infected by HBV, suggesting the existence of alternative receptors allowing viral entry in the absence of  
167 functional NTCP [83].

168 Interestingly, expression of human (but not mouse) NTCP in non-susceptible hepatocarcinoma cells  
169 confers limited susceptibility to infection. For robust infection, addition of dimethyl sulfoxide (DMSO) to culture  
170 medium is essential [13]. The fact that human hepatoma cell lines HepG2 and Huh7 are not susceptible to HBV  
171 and HDV infection without exogenous expression of NTCP is consistent with reports that NTCP expression is  
172 reduced in human hepatocellular carcinoma cells [48, 84]. NTCP expression rapidly decreases over time following  
173 isolation of cultured PTHs, which supports observations that primary human hepatocytes (PHH) remain

174 susceptible to HBV infection *in vitro* only for a few days after isolation [12, 85]. Considering the predominant  
175 expression of NTCP in the liver, this receptor is likely to contribute to the hepatotropism of both viruses [12]. In  
176 addition, NTCP protein sequences vary among mammalian species, which might contribute to the narrow species  
177 tropism of HBV and HDV infection. For example, monkey NTCP does not support HBV and HDV infection  
178 despite a high protein sequence homology to human NTCP. Replacing amino acids 157–165 of nonfunctional  
179 monkey NTCP with the human counterpart conferred susceptibility to both HDV and HBV infection [12]. The  
180 fact that hepatocytes from cynomolgus and rhesus macaques and pigs become fully susceptible to HBV upon  
181 hNTCP expression indicates that NTCP is the key host factor limiting HBV infection in these species [86].

182 As a key host factor enabling HBV and HDV infection *in vitro*, the discovery of NTCP has been crucial  
183 for the development of novel animal models supporting virus infection. Indeed, only chimpanzees and *Tupaia* can  
184 experimentally support HBV and HDV infections [87]. The state-of-the-art mouse model for the study of  
185 HBV/HDV consists of liver-engrafted humanized chimeric uPa/SCID or FRG mice, which support virus entry and  
186 replication, but lack an efficient immune system, limiting the study of virus-host interactions [87]. The recent  
187 development of human NTCP-expressing transgenic mice opened perspectives for the development of novel  
188 immune-competent animal models for the investigation of HDV infection and HDV-induced pathogenesis *in vivo*  
189 [88]. As HBV infection is limited in mouse cells expressing hNTCP, probably due to the lack of a key host factor  
190 [89], it should be noted that hNTCP-transgenic mice are not susceptible to HBV infection. Recently, an elegant  
191 study demonstrated that vector-mediated expression of hNTCP in the hepatocytes of rhesus macaques conferred  
192 susceptibility to HBV infection, providing a robust and relevant model for the study of HBV infection, including  
193 its interaction with adaptive immunity and the understanding of viral clearance [90].

194 Overall, NTCP was identified as the long-sought preS1-specific HBV receptor contributing to HBV liver  
195 tropism and species specificity [13]. Targeting the interactions between the HBV preS1-domain and its receptor  
196 NTCP required for HBV/HDV entry is a promising strategy to block viral entry for both viruses.

197

### 198 **NTCP as a therapeutic target for HBV/HDV infection**

199 Even before the identification of NTCP as HBV/HDV receptor, entry inhibitors derived from the HBV preS1 were  
200 shown to efficiently inhibit HBV infection *in vitro* and *in vivo* [91, 92]. One of these compounds, the myristoylated  
201 preS1-derived peptide (also called Myrcludex B or MyrB), efficiently prevents HBV dissemination *in vivo* and  
202 hinders amplification of the cccDNA pool in infected human hepatocytes [14]. MyrB is the first HBV/HDV entry  
203 inhibitor targeting NTCP to reach clinical trials [93], where it was shown to have a good safety profile with a mild



204 and reversible elevation of serum bile acid salts [93, 94]. Phase IIa clinical studies revealed a marked antiviral  
205 effect of MyrB, as measured by HDV RNA, HBV DNA and improvement of biochemical disease activity (ALT),  
206 when used in combination with IFN therapy, although there was no significant decrease in HBsAg levels. In  
207 monotherapy, however, MyrB did not show significant antiviral activity [94]. Further studies are necessary to  
208 confirm these results obtained in small patient cohorts [95].

209         Importantly, the identification of NTCP as the first HBV/HDV entry receptor has accelerated the  
210 discovery and development of several new potential entry inhibitors. Binding of myristoylated preS1-derived  
211 peptide to NTCP was shown to interfere with the physiological bile acid transport function of NTCP, indicating  
212 that NTCP-inhibiting drugs might be able to block HBV infection [96]. In a study evaluating FDA approved  
213 therapeutics with documented inhibitory effect on NTCP cellular function against HDV entry, three of these  
214 molecules (irbesartan, ezetimibe, and ritonavir) inhibited HDV infection *in vitro* [97]. The inhibitory effect of  
215 ezetimibe on HBV infection had already been described previously without understanding its interactions with  
216 NTCP [98]. In 2014, Watashi *et al.* evaluated the effect of compounds on the early phase of the HBV life cycle to  
217 identify cyclosporine A as an HBV entry inhibitor targeting NTCP [15]. In the same year, Nkongolo *et al.*  
218 characterized the effect of cyclosporine A, a cholestasis-inducing drug inhibiting NTCP bile acid transport [32, 97,  
219 98], against HBV/HDV infection and found that inhibition of entry resulted from interference with the NTCP  
220 receptor [16]. The screening of FDA/EMA-approved drugs or small molecules for interaction with NTCP allowed  
221 the identification of several additional potential HBV/HDV entry inhibitors targeting NTCP [18, 19]. All of these  
222 NTCP-targeting HBV/HDV entry inhibitors concomitantly inhibit the transporter function of NTCP and impair  
223 bile acid uptake into hepatocytes, increasing the risk of adverse effects. NTCP-deficient mice and a patient with  
224 NTCP deficiency were shown to exhibit an elevated level of serum bile acids and to develop related pathologies  
225 including growth retardation and hypercholanemia [101, 102].

226         Two different strategies to selectively inhibit HBV entry without impairing bile acid uptake have been  
227 suggested recently. Shimura *et al.* showed that cyclosporine A derivatives SCY450 and SCY995 inhibit  
228 HBV/HDV entry without interfering with the NTCP transporter activity (see Figure 2) [17]. Tsukuda *et al.*  
229 identified an oligomeric flavonoid, proanthocyanidin (PAC) and its analogs, as a new class of entry inhibitors,  
230 which directly target the preS1-domain of the HBV large envelope protein and thereby prevent its attachment to  
231 NTCP. By directly targeting HBV particles, PAC impairs HBV infectivity without affecting the NTCP-mediated  
232 bile acid transport activity [103]. Further studies are required to determine if these novel inhibitory strategies will  
233 show efficacy *in vivo* and in clinical studies in co-treatment with NUC therapy.

234

235 **NTCP is a host factor for HCV infection**

236 Hepatitis C virus is an enveloped single-stranded positive-sense RNA virus in the *Flaviviridae* family. The  
237 host-cell derived lipid envelope contains the two viral envelope glycoproteins, E1 and E2 [104]. Within the  
238 envelope, an icosahedral capsid contains the RNA genome of 9.6 kilobases. Like HBV and HDV, attachment of  
239 HCV to hepatocytes is mediated by HPSGs on the host cell surface [105–107]. Following attachment, the envelope  
240 glycoprotein E2 mediates interactions with a series of specific cellular entry factors, including CD81 and claudin-  
241 1 (see Figure 2) [108–111]. HCV is internalized via endocytosis in a clathrin- and dynamin-dependent process  
242 [112]. Following fusion with early endosomal membranes, the HCV genome is released into the cytosol, where it  
243 is translated into a polyprotein cleaved by viral and host proteases. The HCV genome is replicated directly into  
244 RNA without passing through a DNA intermediate [113]. Therefore, HCV entry and replication steps are very  
245 distinct from those described for HBV/HDV. Nonetheless, the mutual hepatotropism of these three viruses  
246 mediated by tissue specific factors suggests a possible overlap in usage of common hepatocyte specific host factors  
247 like NTCP.

248         Following establishment of the pivotal role of NTCP for HBV and HDV entry into hepatocytes, a recent  
249 study identified a role for NTCP in HCV infection (see Figure 2). Exogenous overexpression or silencing of NTCP  
250 increased or decreased HCV infection *in vitro*, respectively [114]. Unlike HBV, however, no direct interaction  
251 between HCV envelope proteins and NTCP was identified. Instead, the bile acid transporter function of NTCP  
252 was found to be important for HCV entry [114]. Bile acids are known to modulate cellular antiviral responses by  
253 inhibiting interferon (IFN) type I signaling and thereby decreasing the expression of IFN-stimulated genes (ISGs)  
254 [23, 24]. NTCP was shown to regulate HCV infection by inducing the bile acid-mediated repression of ISG  
255 expression in hepatocytes, including IFITM1, IFITM2 and IFITM3 [114]. These transmembrane proteins are  
256 known to restrict the entry of several viruses, including HCV [115]. IFITM1 blocks the interaction between HCV  
257 and its receptors [116], whereas IFITM2 and IFITM3 inhibit entry at a post-endocytosis step by blocking the  
258 release of virions into the cytoplasm [117]. NTCP facilitates HCV infection by modulating innate antiviral  
259 responses via its bile acid transport function. As bile acids have been shown to enhance HCV replication [118], it  
260 is likely that NTCP expression and activity modulates HCV infection through a multimodal mechanism of action.  
261 Interestingly, MyrB-mediated inhibition of NTCP blocks the import of bile acids, which in turn stimulates the  
262 expression of ISGs, inhibiting HCV entry and infection [114]. However, it still needs to be determined whether  
263 the inhibition of NTCP-mediated bile acid entry affects the HBV life cycle through similar mechanisms as

264 described for HCV. The potential of NTCP-targeting antivirals to enhance innate antiviral responses and to engage  
265 the host immune system to clear infection may be a useful property for the treatment of all hepatotropic viruses,  
266 including HBV, HCV and HDV.

267

## 268 **Conclusions**

269 The discovery of NTCP as the first HBV/HDV receptor was a milestone in the study of the life cycle of these  
270 viruses. This landmark discovery enabled significant progress in understanding HBV/HDV entry and virus-host  
271 interactions. Moreover, based on this discovery, novel infectious model systems based on transduced cell lines  
272 stably expressing NTCP have been developed which allow detailed study of the early steps of the viral life cycle.  
273 By allowing the study of authentic infection in cell lines, these model systems will help to understand the formation  
274 and degradation of HBV cccDNA, which is a key target to achieve the ultimate goal of HBV cure. Robust human  
275 NTCP-expressing animal model systems will enable the *in vivo* validation of virus-host interactions and antiviral  
276 therapies. Moreover, NTCP has been established as an antiviral target, and several molecules targeting NTCP are  
277 in clinical development with the goal to improve current therapies in the future. The recent discovery of NTCP as  
278 a host-dependency factor in HCV infection underscores its essential role in virus-hepatocyte interactions.

279

## 280 **Author contributions**

281 CFE, LH, CCC, ERV, CS, TFB wrote the manuscript.

282

## 283 **Conflicts of interest**

284 The authors have no conflicting interests to disclose.

285

286 **References**

- 287 [1] World Health Organization Global health sector strategy on viral hepatitis 2016-2021, 2016.
- 288 [2] Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ (2015) Estimations of worldwide prevalence of  
289 chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013.  
290 *Lancet* 386: 1546–1555. doi:10.1016/S0140-6736(15)61412-X.
- 291 [3] WHO Global hepatitis report, 2017, 2017.
- 292 [4] Sultanik P, Pol S (2016) Hepatitis Delta Virus: Epidemiology, Natural Course and Treatment. *J Infect*  
293 *Dis Ther* 4: 2–7. doi:10.4172/2332-0877.1000271.
- 294 [5] Chung RT, Baumert TF (2014) Curing Chronic Hepatitis C — The Arc of a Medical Triumph. *New*  
295 *Engl. J. Medecine* 370: 1576–1578. doi:10.1056/NEJMp1401833.
- 296 [6] Werle–Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Treppe C, Marcellin P,  
297 Goodman Z, Delaney WE, Xiong S, Brosgart CL, Chen S, Gibbs CS, Zoulim F (2004) Persistence of  
298 cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.  
299 *Gastroenterology* 126: 1750–1758. doi:10.1053/j.gastro.2004.03.018.
- 300 [7] Papatheodoridis G V., Idilman R, Dalekos GN, Buti M, Chi H, Boemmel F Van, Calleja JL, Sypsa V,  
301 Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskin O, Gatselis N, Hansen BE, Lehretz M,  
302 Revilla J De, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo  
303 M, Esteban R, Janssen HLA, Lampertico P (2017) The Risk of Hepatocellular Carcinoma Decreases  
304 After the First 5 Years of Entecavir or Tenofovir in Caucasians With Chronic Hepatitis B. *Hepatology*  
305 66: 1444–1453. doi:10.1002/hep.29320.
- 306 [8] Baumert TF, Jühling F, Ono A, Hoshida Y (2017) Hepatitis C-related hepatocellular carcinoma in the era  
307 of new generation antivirals. *BMC Med.* 15: 1–10. doi:10.1186/s12916-017-0815-7.
- 308 [9] Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB (2015) Host-targeting agents for treatment of  
309 hepatitis B virus infection. *Curr. Opin. Virol.* 14: 41–46. doi:10.1016/j.coviro.2015.07.009.
- 310 [10] Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I,  
311 Thumann C, Bandiera S, Lütgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-  
312 Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa

- 313 P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E,  
314 Baumert TF (2015) Clearance of persistent hepatitis C virus infection in humanized mice using a  
315 claudin-1-targeting monoclonal antibody. *Nat. Biotechnol.* 33: 549–554. doi:10.1038/nbt.3179.
- 316 [11] Zeisel MB, Baumert TF (2017) Clinical development of hepatitis C virus host-targeting agents. *Lancet*  
317 389: 674–675. doi:10.1016/S0140-6736(17)30043-0.
- 318 [12] Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P,  
319 Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W (2012) Sodium taurocholate cotransporting  
320 polypeptide is a functional receptor for human hepatitis B and D virus. *Elife* 1: e000049.  
321 doi:10.7554/eLife.00049.
- 322 [13] Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Fälth M, Stindt J, Königer C, Nassal M, Kubitz R,  
323 Sülthmann H, Urban S (2014) Hepatitis B and D viruses exploit sodium taurocholate co-transporting  
324 polypeptide for species-specific entry into hepatocytes. *Gastroenterology* 146: 1070–1083.  
325 doi:10.1053/j.gastro.2013.12.024.
- 326 [14] Volz T, Allweiss L, MBarek M Ben, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S,  
327 Petersen J, Lütgehetmann M, Dandri M (2013) The entry inhibitor Myrcludex-B efficiently blocks  
328 intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. *J. Hepatol.* 58:  
329 861–867. doi:10.1016/j.jhep.2012.12.008.
- 330 [15] Watashi K, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S,  
331 Borroto-Esoda K, Sugiyama M, Tanaka Y, Kanai Y, Kusuhara H, Mizokami M, Wakita T (2014)  
332 Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting  
333 a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). *Hepatology* 59: 1726–  
334 1737. doi:10.1002/hep.26982.
- 335 [16] Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S,  
336 Urban S (2014) Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-  
337 independent interference with the NTCP receptor. *J. Hepatol.* 60: 723–731.  
338 doi:10.1016/j.jhep.2013.11.022.
- 339 [17] Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS,  
340 Miyake T, Sugiyama M, Ogasawara Y, Park S, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita

- 341 T (2017) Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP  
342 transporter activity. *J. Hepatol.* 66: 685–692. doi:10.1016/j.jhep.2016.11.009.
- 343 [18] Donkers JM, Zehnder B, Westen GJP Van, Kwakkenbos MJ, Ijzerman AP, Elferink RPJO, Beuers U,  
344 Urban S, van de Graaf SFJ (2017) Reduced hepatitis B and D viral entry using clinically applied drugs as  
345 novel inhibitors of the bile acid transporter NTCP. *Sci. Rep.* 7: 1–13. doi:10.1038/s41598-017-15338-0.
- 346 [19] Kaneko M, Futamura Y, Tsukuda S, Kondoh Y, Sekine T, Hirano H, Fukano K, Ohashi H, Saso W,  
347 Morishita R, Matsunaga S, Kawai F, Ryo A, Park S-Y, Suzuki R, Aizaki H, Ohtani N, Sureau C, Wakita  
348 T, Osada H, Watashi K (2018) Chemical array system, a platform to identify novel hepatitis B virus  
349 entry inhibitors targeting sodium taurocholate cotransporting polypeptide. *Sci. Rep.* 8: 1–13.  
350 doi:10.1038/s41598-018-20987-w.
- 351 [20] Verrier ER, Colpitts CC, Schuster C, Zeisel MB, Baumert TF (2016) Cell culture models for the  
352 investigation of Hepatitis B and D Virus infection. *Viruses* 8: 1–10. doi:10.3390/v8090261.
- 353 [21] Döring B, Lütteke T, Geyer J, Petzinger E (2012) The SLC10 Carrier Family: Transport Functions and  
354 Molecular Structure. *Curr. Top. Membr.* 70: 105–168. doi:10.1016/B978-0-12-394316-3.00004-1.
- 355 [22] Esteller A (2008) Physiology of bile secretion. *World J. Gastroenterol.* 14: 5641–5649.  
356 doi:10.3748/wjg.14.5641.
- 357 [23] Podevin P, Rosmorduc O, Conti F, Calmus Y, Meier PJ, Poupon R (1999) Bile Acids Modulate the  
358 Interferon Signalling Pathway. *Hepatology* 29: 1840–1847.
- 359 [24] Graf D, Haselow K, Münks I, Bode JG, Häussinger D (2010) Inhibition of interferon- $\alpha$ -induced signaling  
360 by hyperosmolarity and hydrophobic bile acids. *Biol. Chem* 391: 1175–1187. doi:10.1515/BC.2010.108.
- 361 [25] Slijepcevic D, van de Graaf FJ (2017) Bile Acid Uptake Transporters as Targets for Therapy. *Dig. Dis.*  
362 35: 251–258. doi:10.1159/000450983.
- 363 [26] Geyer J, Wilke T, Petzinger E (2006) The solute carrier family SLC10: more than a family of bile acid  
364 transporters regarding function and phylogenetic relationships. *Naunyn-Schmiedeberg's Arch Pharmacol*  
365 372: 413–431. doi:10.1007/s00210-006-0043-8.
- 366 [27] Hagenbuch B, Meier PJ (1994) Molecular Cloning, Chromosomal Localization, and Functional  
367 Characterization of a Human Liver Na<sup>+</sup>/Bile Acid Cotransporter. *J. Clin. Invest.* 93: 1326–1331.

- 368 [28] Mukhopadhyay S, Ananthanarayanan M, Stieger B, Meier PJ, Suchy FJ, Anwer MS (1998) Sodium  
369 Taurocholate Cotransporting Polypeptide Is a Serine, Threonine Phosphoprotein and Is  
370 Dephosphorylated by Cyclic Adenosine Monophosphate. *Hepatology* 92: 1629–1636.
- 371 [29] da Silva TC, Polli JE, Swaan PW (2013) The solute carrier family 10 (SLC10): beyond bile acid  
372 transport. *Mol. Aspects Med.* 34: 252–269. doi:10.1016/j.mam.2012.07.004.The.
- 373 [30] Hu N-J, Iwata S, Cameron AD, Drew D (2011) Crystal structure of a bacterial homologue of the bile  
374 acid sodium symporter ASBT. *Nature* 478: 408–411. doi:10.1038/nature10450.
- 375 [31] Dawson PA (2011) Role of the Intestinal Bile Acid Transporters in Bile Acid and Drug Disposition.  
376 *Handb. Exp. Pharmacol.* 201: 169–203. doi:10.1007/978-3-642-14541-4.
- 377 [32] Dong Z, Ekins S, Polli JE (2013) Structure Activity Relationship for FDA Approved Drugs as Inhibitors  
378 of the Human Sodium Taurocholate Co-transporting Polypeptide (NTCP). *Mol Pharm.* 10: 1008–1019.  
379 doi:10.1021/mp300453k.Structure.
- 380 [33] Chiang JYL (2003) Bile Acid Regulation of Hepatic Physiology III. Bile acids and nuclear receptors.  
381 *Am J Physiol Gastrointest Liver Physiol* 284: G349–G356.
- 382 [34] Goodwin B, Jones SA, Price RR, Watson MA, Mckee DD, Moore LB, Galardi C, Wilson JG, Lewis  
383 MC, Roth ME, Maloney PR, Willson TM, Kliewer SA (2000) A Regulatory Cascade of the Nuclear  
384 Receptors FXR , SHP-1 , and LRH-1 Represses Bile Acid Biosynthesis. *Mol. Cell* 6: 517–526.
- 385 [35] Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ (2000) Molecular  
386 Basis for Feedback Regulation of Bile Acid Synthesis by Nuclear Receptors. *Mol. Cell* 6: 507–515.
- 387 [36] Jonker JW, Stedman CAM, Liddle C, Downes M (2009) Hepatobiliary ABC transporters: physiology,  
388 regulation and implications for disease. *Front. Biosci.* 14: 4904–4920. doi:10.2741/3576.
- 389 [37] Chiang JYL (2009) Bile acids: regulation of synthesis. *J. Lipid Res.* 50: 1955–1966.  
390 doi:10.1194/jlr.R900010-JLR200.
- 391 [38] Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Hofmann AF, Meier PJ (1998) The  
392 Sister of P-glycoprotein Represents the Canalicular Bile Salt Export Pump of Mammalian Liver. *J. Biol.*  
393 *Chem.* 273: 10046–10050.
- 394 [39] Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, Suchy FJ (2001) Human

- 395 Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor. *J.*  
396 *Biol. Chem.* 276: 28857–28865. doi:10.1074/jbc.M011610200.
- 397 [40] Denson LA, Sturm E, Echevarria W, Zimmerman TL, Makishima M, Mangelsdorf DJ, Karpen SJ (2001)  
398 The Orphan Nuclear Receptor, shp, Mediates Bile Acid–Induced Inhibition of the Rat Bile Acid  
399 Transporter, ntcp. *Gastroenterology* 121: 140–147. doi:10.1053/gast.2001.25503.
- 400 [41] Jung D, Hagenbuch B, Fried M, Meier PJ, Kullak-Ublick GA (2004) Role of liver-enriched transcription  
401 factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene. *Am J Physiol*  
402 *Gastrointest Liver Physiol* 286: 752–761.
- 403 [42] Geier A, Martin I V, Dietrich CG, Balasubramanian N, Strauch S, Suchy FJ, Gartung C, Trautwein C,  
404 Ananthanarayanan M (2008) Hepatocyte nuclear factor-4a is a central transactivator of the mouse Ntcp  
405 gene. *Am J Physiol Gastrointest Liver Physiol* 295: 226–233. doi:10.1152/ajpgi.00012.2008.
- 406 [43] Li D, Zimmerman TL, Thevananther S, Lee H-Y, Kurie JM, Karpen SJ (2002) Interleukin-1b-mediated  
407 Suppression of RXR:RAR Transactivation of the Ntcp Promoter Is JNK-dependent. *J. Biol. Chem.* 277:  
408 31416–31422. doi:10.1074/jbc.M204818200.
- 409 [44] Siewert E, Dietrich CG, Lammert F, Heinrich PC, Matern S, Gartung C, Geier A (2004) Interleukin-6  
410 regulates hepatic transporters during acute-phase response. *Biochem. Biophys. Res. Commun.* 322: 232–  
411 238. doi:10.1016/j.bbrc.2004.07.102.
- 412 [45] Le Vee M, Lecureur V, Stieger B, Fardel O (2009) Regulation of Drug Transporter Expression in  
413 Human Hepatocytes Exposed to the Proinflammatory Cytokines Tumor Necrosis Factor- $\alpha$  or Interleukin-  
414 6. *Drug Metab. Dispos.* 37: 685–693. doi:10.1124/dmd.108.023630.pump.
- 415 [46] Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall H-U, Zatloukal K, Denk H, Trauner M (2003)  
416 Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. *J. Hepatol.* 38:  
417 717–727. doi:10.1016/S0.
- 418 [47] Kojima H, Nies AT, König J, Hagmann W, Spring H, Uemura M, Fukui H, Keppler D (2003) Changes  
419 in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis.  
420 *J. Hepatol.* 39: 693–702. doi:10.1016/S0168-8278(03)00410-0.
- 421 [48] Kang J, Wang J, Cheng J, Cao Z, Chen R, Li H, Liu S, Chen X, Sui J, Lu F (2017) Down-regulation of



422 NTCP expression by cyclin D1 in hepatitis B virus-related hepatocellular carcinoma has clinical  
423 significance. *Oncotarget* 8: 56041–56050.

424 [49] Anwer MS (2014) Role of protein kinase C isoforms in bile formation and cholestasis. *Hepatology* 60:  
425 1090–1097. doi:10.1002/hep.27088.Role.

426 [50] Grüne S, Engelking LR, Anwer MS (1993) Role of Intracellular Calcium and Protein Kinases in the  
427 Activation of Hepatic Na<sup>+</sup>/Taurocholate Cotransport by Cyclic AMP. *J. Biol. Chem.* 268: 17734–17741.

428 [51] Webster CRL, Blanch C, Anwer MS (2002) Role of PP2B in cAMP-induced dephosphorylation and  
429 translocation of NTCP. *Am J Physiol Gastrointest Liver Physiol* 283: G44–G50.

430 [52] Anwer MS, Gillin H, Mukhopadhyay S, Balasubramanian N, Suchy FJ, Ananthanarayanan M (2005)  
431 Dephosphorylation of Ser-226 Facilitates Plasma Membrane Retention of Ntcp. *J. Biol. Chem.* 280:  
432 33687–33692. doi:10.1074/jbc.M502151200.

433 [53] Ho RH, Leake BF, Roberts RL, Lee W, Kim RB (2004) Ethnicity-dependent Polymorphism in Na<sup>+</sup>-  
434 taurocholate Cotransporting Polypeptide (SLC10A1) Reveals a Domain Critical for Bile Acid Substrate  
435 Recognition. *J. Biol. Chem.* 279: 7213–7222. doi:10.1074/jbc.M305782200.

436 [54] Pan W, Song I-S, Shin H-J, Kim M-H, Choi Y-L, Lim J, Kim W-Y, Lee S-S, Shin J-G (2011) Genetic  
437 polymorphisms in Na<sup>+</sup>-taurocholate co-transporting polypeptide (NTCP) and ileal apical sodium-  
438 dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among  
439 Asian populations. *Xenobiotica* The 41: 501–510. doi:10.3109/00498254.2011.555567.

440 [55] Sureau C, Guerra B, Lanford RE (1993) Role of the Large Hepatitis B Virus Envelope Protein in  
441 Infectivity of the Hepatitis Delta Virion. *J. Virol.* 67: 366–372.

442 [56] Nassal M (2015) HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic  
443 hepatitis B. *Gut* 64: 1972–1984. doi:10.1136/gutjnl-2015-309809.

444 [57] Lucifora J, Protzer U (2016) Attacking hepatitis B virus cccDNA - The holy grail to hepatitis B cure. *J.*  
445 *Hepatol.* 64: S41-8. doi:10.1016/j.jhep.2016.02.009.

446 [58] Rizzetto M, Hoyer B, Canese MG, Shih JW, Purcellt RH, Gerin JL (1980) Delta agent: Association of  
447 delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. *PNAS*  
448 77: 6124–6128.

- 449 [59] Sureau C, Negro F (2016) The hepatitis delta virus: Replication and pathogenesis. *J. Hepatol.* 64: S102–  
450 S116. doi:10.1016/j.jhep.2016.02.013.
- 451 [60] Marsh M, Helenius A (2006) Virus Entry: Open Sesame. *Cell* 124: 729–740.  
452 doi:10.1016/j.cell.2006.02.007.
- 453 [61] Abou Jaoude G, Sureau C (2005) Role of the Antigenic Loop of the Hepatitis B Virus Envelope Proteins  
454 in Infectivity of Hepatitis Delta Virus. *J. Virol.* 79: 10460–10466. doi:10.1128/JVI.79.16.10460.
- 455 [62] Abou Jaoude G, Sureau C (2007) Entry of Hepatitis Delta Virus Requires the Conserved Cysteine  
456 Residues of the Hepatitis B Virus Envelope Protein Antigenic Loop and Is Blocked by Inhibitors of  
457 Thiol-Disulfide Exchange. *J. Virol.* 81: 13057–13066. doi:10.1128/JVI.01495-07.
- 458 [63] Persing DH, Varmus HE, Ganem DON (1987) The preS1 Protein of Hepatitis B Virus Is Acylated at Its  
459 Amino Terminus with Myristic Acid. *J. Virol.* 61: 1672–1677.
- 460 [64] Gripon P, Seyec JLE, Rumin S, Guguen-Guillouzo C (1995) Myristylation of the Hepatitis B Virus  
461 Large Surface Protein Is Essential for Viral Infectivity. *Virology* 213: 292–299.
- 462 [65] Bruss V, Hagelstein J, Gerhardt E, Galle PR (1996) Myristylation of the Large Surface Protein Is  
463 Required for Hepatitis B Virus in Vitro Infectivity. *Virology* 218: 396–399.
- 464 [66] Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-  
465 Guillouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. *Proc. Natl. Acad. Sci.*  
466 *U. S. A.* 99: 15655–60. doi:10.1073/pnas.232137699.
- 467 [67] Spillmann D (2001) Heparan sulfate: Anchor for viral intruders? *Biochimie* 83: 811–817.
- 468 [68] Bartlett AH, Park PW (2015) Proteoglycans in host–pathogen interactions: molecular mechanisms and  
469 therapeutic implications. *Expert Rev Mol Med* 12: e5. doi:10.1017/S1462399409001367.
- 470 [69] Schulze A, Gripon P, Urban S (2007) Hepatitis B Virus Infection Initiates With a Large Surface Protein-  
471 Dependent Binding to Heparan Sulfate Proteoglycans. *Hepatology* 46: 1759–1768.  
472 doi:10.1002/hep.21896.
- 473 [70] Sureau C, Salisse J (2013) A Conformational Heparan Sulfate Binding Site Essential to Infectivity  
474 Overlaps with the Conserved Hepatitis B Virus a-Determinant. *Hepatology* 57: 985–94.  
475 doi:10.1002/hep.26125.

- 476 [71] Verrier ER, Colpitts CC, Bach C, Heydmann L, Weiss A, Renaud M, Durand SC, Habersetzer F,  
477 Durantel D, Abou-Jaoudé G, López Ledesma MM, Felmlee DJ, Soumillon M, Croonenborghs T, Pochet  
478 N, Nassal M, Schuster C, Brino L, Sureau C, Zeisel MB, Baumert TF (2016) A targeted functional RNA  
479 interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses. *Hepatology* 63:  
480 35–48. doi:10.1002/hep.28013.
- 481 [72] Leistner CM, Gruen-Bernhard S, Glebe D (2008) Role of glycosaminoglycans for binding and infection  
482 of hepatitis B virus. *Cell. Microbiol.* 10: 122–133. doi:10.1111/j.1462-5822.2007.01023.x.
- 483 [73] Neurath AR, Kent SBH, Strick N, Parker K (1986) Identification and Chemical Synthesis of a Host Cell  
484 Receptor Binding Site on Hepatitis B Virus. *Cell* 46: 429–436.
- 485 [74] Neurath BAR, Strick N, Sproul P (1992) Search for Hepatitis B Virus Cell Receptors Reveals Binding  
486 Sites for Interleukin 6 on the Virus Envelope Protein. *J. Exp. Med.* 175: 461–469.
- 487 [75] Pontisso P, Ruvoletto MG, Tiribelli C, Gerlich WH, Ruop A, Alberti A (1992) The preS1 domain of  
488 hepatitis B virus and IgA cross-react in their binding to the hepatocyte surface. *J. Gen. Virol.* 73: 2041–  
489 2045.
- 490 [76] Ryu CJ, Cho D, Gripon P, Kim HS, Guguen-Guillouzo C, Hong HJ (2000) An 80-Kilodalton Protein  
491 That Binds to the Pre-S1 Domain of Hepatitis B Virus. *J. Virol.* 74: 110–116.
- 492 [77] Falco S De, Ruvoletto MG, Verdoliva A, Ruvo M, Raucci A, Marino M, Senatore S, Cassani G, Alberti  
493 A, Pontisso P, Fassina G (2001) Cloning and Expression of a Novel Hepatitis B Virus-binding Protein  
494 from HepG2 Cells. *J. Biol. Chem.* 276: 36613–36623. doi:10.1074/jbc.M102377200.
- 495 [78] Li D, Wang XZ, Ding J, Yu J-P (2005) NACA as a Potential Cellular Target of Hepatitis B Virus PreS1  
496 Protein. *Dig. Dis. Sci.* 50: 1156–1160. doi:10.1007/s10620-005-2724-4.
- 497 [79] Zhong G, Yan H, Wang H, He W, Jing Z, Qi Y, Fu L, Gao Z, Huang Y, Xu G, Feng X, Sui J, Li W  
498 (2013) Sodium Taurocholate Cotransporting Polypeptide Mediates Woolly Monkey Hepatitis B Virus  
499 Infection of Tupaia Hepatocytes. *J. Virol.* 87: 7176–7184. doi:10.1128/JVI.03533-12.
- 500 [80] Peng L, Zhao Q, Li Q, Li M, Li C, Xu T, Jing X, Zhu X, Wang Y, Li F, Liu R, Zhong C, Pan Q, Zeng B,  
501 Liao Q, Hu B, Hu Z, Huang Y, Sham P, Liu J, Xu S, Wang J, Gao Z, Wang Y (2015) The p.Ser267Phe  
502 Variant in SLC10A1 Is Associated With Resistance to Chronic Hepatitis B. *Hepatology* 61: 1251–1260.

- 503 doi:10.1002/hep.27608.
- 504 [81] Lee HW, Park HJ, Jin B, Dezhbord M, Kim DY, Han KH, Ryu WS, Kim S, Ahn SH (2017) Effect of  
505 S267F variant of NTCP on the patients with chronic hepatitis B. *Sci. Rep.* 7: 1–7. doi:10.1038/s41598-  
506 017-17959-x.
- 507 [82] An P, Zeng Z, Winkler CA (2018) The loss-of-function S267F variant in HBV receptor NTCP reduces  
508 human risk to HBV infection and disease progression. *J Infect Dis.* Jun 14:  
509 doi:10.1093/infdis/jiy355/5037696.
- 510 [83] Hu H, Liu J, Lin Y-L, Luo W, Chu Y-J, Chang C-L, Jen C-L, Lee M-H, Lu S-N, Wang L-Y, You S-L,  
511 Yang H-I, Chen C-J (2016) The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated  
512 with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with  
513 chronic hepatitis B. *Gut* 65: 1514–1521. doi:10.1136/gutjnl-2015-310686.
- 514 [84] Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H, Trauner M (2005)  
515 Hepatobiliary transporter expression in human hepatocellular carcinoma. *Liver Int.* 25: 367–379.  
516 doi:10.1111/j.1478-3231.2005.01033.x.
- 517 [85] Gripon P, Diot C, Theze N, Fourel I, Loreal O, Brechot C, Guguen-Guillouzo C (1988) Hepatitis B  
518 Virus Infection of Adult Human Hepatocytes Cultured in the Presence of Dimethyl Sulfoxide. *J. Virol.*  
519 62: 4136–4143.
- 520 [86] Lempp FA, Wiedtke E, Qu B, Roques P, Chemin I, Vondran FWR, Grand R Le, Grimm D, Urban S  
521 (2017) Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus  
522 infection in macaque and pig hepatocytes. *Hepatology* 66: 703–716.
- 523 [87] Allweiss L, Dandri M (2016) Experimental in vitro and in vivo models for the study of human hepatitis  
524 B virus infection. *J. Hepatol.* 64: S17–S31. doi:10.1016/j.jhep.2016.02.012.
- 525 [88] He W, Ren B, Mao F, Jing Z, Li Y, Liu Y, Peng B, Yan H, Qi Y, Sun Y, Guo J-T, Sui J, Wang F, Li W  
526 (2015) Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate co-transporting  
527 Polypeptide. *PLoS Pathog.* 11: 1–17. doi:10.1371/journal.ppat.1004840.
- 528 [89] Lempp FA, Mutz P, Lipps C, Wirth D, Bartenschlager R, Urban S (2016) Evidence that hepatitis B virus  
529 replication in mouse cells is limited by the lack of a host cell dependency factor. *J. Hepatol.* 64: 556–

- 530 564. doi:10.1016/j.jhep.2015.10.030.
- 531 [90] Burwitz BJ, Wettengel JM, Mück-Häusl MA, Ringelhan M, Ko C, Festag MM, Hammond KB, Northrup  
532 M, Bimber BN, Jacob T, Reed JS, Norris R, Park B, Moller-Tank S, Esser K, Greene JM, Wu HL,  
533 Abdulhaqq S, Webb G, Sutton WF, Klug A, Swanson T, Legasse AW, Vu TQ, Asokan A, Haigwood  
534 NL, Protzer U, Sacha JB (2017) Hepatocytic expression of human sodium-taurocholate cotransporting  
535 polypeptide enables hepatitis B virus infection of macaques. *Nat. Commun.* 8: 1–10.  
536 doi:10.1038/s41467-017-01953-y.
- 537 [91] Gripon P, Cannie I, Urban S (2005) Efficient Inhibition of Hepatitis B Virus Infection by Acylated  
538 Peptides Derived from the Large Viral Surface Protein. *J. Virol.* 79: 1613–1622.  
539 doi:10.1128/JVI.79.3.1613.
- 540 [92] Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz T, von Weizsäcker F, Haberkorn U, Fischer L,  
541 Pollok J-M, Erbes B, Seitz S, Urban S (2008) Prevention of hepatitis B virus infection in vivo by entry  
542 inhibitors derived from the large envelope protein. *Nat. Biotechnol.* 26: 335–341. doi:10.1038/nbt1389.
- 543 [93] Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban  
544 S, Haefeli WE (2016) First-in-human application of the novel hepatitis B and hepatitis D virus entry  
545 inhibitor myrcludex B. *J. Hepatol.* 65: 483–489. doi:10.1016/j.jhep.2016.04.013.
- 546 [94] Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp  
547 FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S (2016) Treatment of chronic  
548 hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. *J. Hepatol.* 65:  
549 490–498. doi:10.1016/j.jhep.2016.04.016.
- 550 [95] Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri-Petersen M, Bremer B, Voronkova N,  
551 Schöneweis K, Pathil A, Burhenne J, Haag M, Schwab M, Haefeli W-E, Wiesch JSZ, Alexandrov A,  
552 Urban S (2018) Final results of a multicenter, open-label phase 2b clinical trial to assess safety and  
553 efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-  
554 infection. *J. Hepatol.* 68: S3.
- 555 [96] König A, Döring B, Mohr C, Geipel A, Geyer J, Glebe D (2014) Kinetics of the bile acid transporter and  
556 hepatitis B virus receptor Na<sup>+</sup>/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. *J.*  
557 *Hepatol.* 61: 867–875. doi:10.1016/j.jhep.2014.05.018.

- 558 [97] Blanchet M, Sureau C, Labonté P (2014) Use of FDA approved therapeutics with hNTCP metabolic  
559 inhibitory properties to impair the HDV lifecycle. *Antiviral Res.* 106: 111–115.  
560 doi:10.1016/j.antiviral.2014.03.017.
- 561 [98] Lucifora J, Esser K, Protzer U (2013) Ezetimibe blocks hepatitis B virus infection after virus uptake into  
562 hepatocytes. *Antiviral Res.* 97: 195–197. doi:10.1016/j.antiviral.2012.12.008.
- 563 [99] Azer SA, Stacey H (1993) Differential Effects of Cyclosporin A on the transport of bile acids by human  
564 hepatocytes. *Biochem. Pharmacol.* 46: 813–819.
- 565 [100] Mita S, Suzuki H, Akita H, Hayashi H, Onuki R, Hofmann AF, Sugiyama Y (2006) Inhibition of Bile  
566 Acid Transport across Na<sup>+</sup>/Taurocholate Cotransporting Polypeptide (SLC10A1) and Bile Salt Export  
567 Pump (ABCB 11)-Coexpressing LLC-PK1 Cells by Cholestasis-Inducing Drugs. *Drug Metab. Dispos.*  
568 34: 1575–1581. doi:10.1124/dmd.105.008748.basolateral.
- 569 [101] Slijepcevic D, Kaufman C, Wichers CGK, Gilgioni EH, Lempp FA, Duijst S, de Waart DR, Oude  
570 Elferink RPJ, Mier W, Stieger B, Beuers U, Urban S, van de Graaf SFJ (2015) Impaired Uptake of  
571 Conjugated Bile Acids and Hepatitis B Virus Pres1-Binding in Na<sup>+</sup>-Taurocholate Cotransporting  
572 Polypeptide Knockout Mice. *Hepatology* 62: 207–219. doi:10.1002/hep.27694.
- 573 [102] Vaz M, Paulusma CC, Huidekoper H, Ru M De, Lim C, Koster J, Ho-Mok K, Bootsma AH, Groen AK,  
574 Schaap FG, Oude Elferink RPJ, Waterham HR, Wanders RJA (2015) Sodium Taurocholate  
575 Cotransporting Polypeptide (SLC10A1) Deficiency: Conjugated Hypercholanemia Without a Clear  
576 Clinical Phenotype. *Hepatology* 61: 260–267. doi:10.1002/hep.27240.
- 577 [103] Tsukuda S, Watashi K, Hojima T, Isogawa M, Iwamoto M, Omagari K, Suzuki R, Aizaki H, Kojima S,  
578 Sugiyama M, Saito A, Tanaka Y, Mizokami M, Sureau C, Wakita T (2017) A New Class of Hepatitis B  
579 and D Virus Entry Inhibitors, Proanthocyanidin and Its Analogs, That Directly Act on the Viral Large  
580 Surface Proteins. *Hepatology* 65: 1104–1116. doi:10.1002/hep.28952.
- 581 [104] Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski A V, Cygan A, Price AA, Yost SA,  
582 Bohannon CD, Jacob J, Grakoui A, Marcotrigiano J (2014) Structure of the Core Ectodomain of the  
583 Hepatitis C Virus Envelope Glycoprotein 2. *Nature* 509: 381–384. doi:10.1038/nature13117.Structure.
- 584 [105] Barth H, Schäfer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, van  
585 Kuppevelt TH, Depla E, von Weizsäcker F, Blum HE, Baumert TF (2003) Cellular Binding of Hepatitis

586 C Virus Envelope Glycoprotein E2 Requires Cell Surface Heparan Sulfate. *J. Biol. Chem.* 278: 41003–  
587 41012. doi:10.1074/jbc.M302267200.

588 [106] Shi Q, Jiang J, Luo G (2013) Syndecan-1 Serves as the Major Receptor for Attachment of Hepatitis C  
589 Virus to the Surfaces of Hepatocytes. *J. Virol.* 87: 6866–6875. doi:10.1128/JVI.03475-12.

590 [107] Lefevre M, Felmlee DJ, Parnot M, Baumert TF, Schuster C (2014) Syndecan 4 Is Involved in Mediating  
591 HCV Entry through Interaction with Lipoviral Particle-Associated Apolipoprotein E. *PLoS One* 9: 3–10.  
592 doi:10.1371/journal.pone.0095550.

593 [108] Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D,  
594 Grandi G, Abrignani S (1998) Binding of Hepatitis C Virus to CD81. *Science* (80-. ). 282: 938–942.

595 [109] Owen DM, Huang H, Ye J, Gale Jr. M (2010) Apolipoprotein E on Hepatitis C Virion Facilitates  
596 Infection through Interaction with Low Density Lipoprotein Receptor. *Virology* 394: 99–108.  
597 doi:10.1016/j.virol.2009.08.037.

598 [110] Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset F-L, Wakita T, Jaeck D,  
599 Doffoel M, Royer C, Soulier E, Schvoerer E, Schuster C, Stoll-Keller F, Bartenschlager R, Pietschmann  
600 T, Barth H, Baumert TF (2007) Scavenger Receptor Class B Type I Is a Key Host Factor for Hepatitis C  
601 Virus Infection Required for an Entry Step Closely Linked to CD81. *Hepatology* 46: 1–3.  
602 doi:10.1002/hep.21994.

603 [111] Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S,  
604 Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset F-L, Rothenberg SM, Pietschmann T,  
605 Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF (2011)  
606 EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.  
607 *Nat. Med.* 17: 589–595. doi:10.1038/nm.2341.

608 [112] Farquhar MJ, Hu K, Harris HJ, Davis C, Brimacombe CL, Fletcher SJ, Baumert TF, Rappoport JZ, Balfe  
609 P, McKeating JA (2012) Hepatitis C Virus Induces CD81 and Claudin-1 Endocytosis. *J. Virol.* 86:  
610 4305–4316. doi:10.1128/JVI.06996-11.

611 [113] Dubuisson J, Cosset F-L (2014) Virology and cell biology of the hepatitis C virus life cycle – An update.  
612 *J. Hepatol.* 61: S3–S13. doi:10.1016/j.jhep.2014.06.031.

- 613 [114] Verrier ER, Colpitts CC, Bach C, Heydmann L, Zona L, Xiao F, Thumann C, Crouchet E, Gaudin R,  
614 Sureau C, Cosset F-L, McKeating JA, Pessaux P, Hoshida Y, Schuster C, Zeisel MB, Baumert TF  
615 (2016) Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus  
616 Infection of Hepatocytes. *Cell Rep.* 17: 1357–1368. doi:10.1016/j.celrep.2016.09.084.
- 617 [115] Smith SE, Weston S, Kellam P, Marsh M (2014) IFITM proteins — cellular inhibitors of viral entry.  
618 *Curr. Opin. Virol.* 4: 71–77. doi:10.1016/j.coviro.2013.11.004.
- 619 [116] Wilkins C, Woodward J, Lau DT-Y, Barnes A, Joyce M, McFarlane N, McKeating J, Tyrrell DL, Gale  
620 Jr. M (2013) IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. *Hepatology* 57: 461–  
621 469. doi:10.1002/hep.26066.IFITM1.
- 622 [117] Narayana SK, Helbig KJ, McCartney EM, Eyre NS, Bull RA, Eltahla A, Lloyd AR, Beard MR (2015)  
623 The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C  
624 Virus Entry. *J. Biol. Chem.* 290: 25946–25959. doi:10.1074/jbc.M115.657346.
- 625 [118] Chang K-O, George DW (2007) Bile Acids Promote the Expression of Hepatitis C Virus in Replicon-  
626 Harboring Cells. *J. Virol.* 81: 9633–9640. doi:10.1128/JVI.00795-07.
- 627
- 628




629 **Figure legends**

630 **Fig. 1 Model of the functional role of NTCP in hepatic bile acid transport and metabolism.** Transport of bile  
631 acids from portal blood into hepatocytes *via* NTCP depends on a sodium gradient and is inhibited by CsA or  
632 ezetimibe. Secretion into the bile canaliculus *via* bile salt export pump (BSEP) in an ATP-dependent manner and  
633 synthesis from cholesterol are regulated by bile acid-mediated activation of FXR. cAMP mediates  
634 dephosphorylation and membrane translocation of NTCP. NTCP: Sodium taurocholate co-transporting  
635 polypeptide; BSEP: bile salt export pump; FXR: Farnesoid X Receptor; SHP: small heterodimer partner; CYP7A1:  
636 cholesterol 7 $\alpha$ -hydroxylase; BA: bile acid; TJ: tight junction; CsA: cyclosporin A; cAMP: cyclic adenosine  
637 monophosphate

638  
639 **Fig. 2 Model of interactions between NTCP and the entry of HBV, HDV, and HCV in hepatocytes.** After  
640 initial attachment to HSPG including GPC5, HBV and HDV virions bind to the receptor NTCP through the preS1-  
641 domain of the large envelope protein. NTCP inhibitors CsA and ezetimibe block viral entry like preS1-derived  
642 MyrB and CsA-derived SCY995. NTCP modulates HCV infection by interfering with innate immune responses.  
643 Bile acids interfere with the IFN signaling pathway and thereby favor HCV entry. Inhibition of NTCP-mediated  
644 bile acid import into hepatocytes promotes inhibition of HCV entry through the upregulation of ISGs including  
645 *IFITMs*. HBV: hepatitis B virus; HCV: hepatitis C virus; HDV: hepatitis D virus; HSPG: heparan sulfate  
646 proteoglycan; GPC5: glypican-5; NTCP: Sodium taurocholate co-transporting polypeptide; MyrB: myrcludex B;  
647 CsA: cyclosporin A; SCY995: synthesized CsA derivative 995; IFN: interferon; IFNAR: IFN- $\alpha/\beta$  receptor; JAK:  
648 Janus kinase; STAT: signal transducer and activator of transcription; IRF9: Interferon regulatory factor 9; ISRE:  
649 IFN-sensitive response element; ISG: IFN-stimulated gene; IFITM: IFN-induced transmembrane protein; CLDN1:  
650 Claudin 1; CD81: cluster of differentiation 81; BA: bile acid; TJ: tight junction

651


652 Figure 1



653

654

655 Figure 2



656